One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.

Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.

Day 4 was a half day closeout to the EULAR 2023 Congress.

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.

There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.

 

Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.

A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.

Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.